Month: May 2022

MINNEAPOLIS, May 10, 2022 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE) announced today its results for the first quarter ended March 31, 2022, which included the following highlights:Generated $1.9 million in total revenue for the first quarter 2022, up 17% sequentially from the fourth quarter of 2021 Received a Category III CPT Code effective January 1, 2022, specifically for the use of therapeutic ultrafiltration, thereby increasing reimbursement to professionals and facilities, an important step in advancing Aquadex to standard of care On track to enroll first patients in REVERSE-HF, a randomized controlled multi-center clinical trial designed to validate clinical outcomes and the economic value of Aquadex therapy First quarter 2022 cash flow from operations improved $0.6 million compared to the prior-year period“I am...

Topline data for baxdrostat (CIN-107) in BrigHtn Phase 2 trial for treatment-resistant hypertension (rHTN) expected in 2H 2022 Topline data for baxdrostat (CIN-107) in HALO Phase 2 trial for uncontrolled hypertension (uHTN) expected in 2H 2022 Phase 2 figHTN-CKD trial evaluating baxdrostat’s (CIN-107) utility in ameliorating complications of chronic kidney disease (CKD) initiated in April 2022 WALTHAM, Mass., May 10, 2022 (GLOBE NEWSWIRE) — CinCor Pharma, Inc. (NASDAQ: CINC) today announced financial results for the first quarter ended March 31, 2022 and provided a corporate update. “In Q1 2022 CinCor continued its strong momentum by raising approximately $194 million in its IPO despite difficult market conditions, extending its expected cash runway through 2024, including its ongoing and currently planned Phase 2 and Phase 3 clinical...

Four Clinical Readouts Anticipated Throughout 2022Mechanistic Data on FS118 Demonstrating Shedding Mechanism and LAG-3 Reduction Presented at the 2022 American Association for Cancer Research (AACR) Annual Meeting Company To Host Conference Call Today at 9:00 a.m. EDTCAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., May 10, 2022 (GLOBE NEWSWIRE) — F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing next-generation immunotherapies to transform the lives of patients with cancer, today announced first quarter 2022 financial results and provided a corporate update. “This year is one of the most important years in F-star’s history, with data readouts expected across all four of our clinical programs, expansion of our partnering activities, and continued...

CHICAGO, May 10, 2022 (GLOBE NEWSWIRE) — GCM Grosvenor (Nasdaq: GCMG), a leading global alternative asset management solutions provider, today reported strong results for the first quarter ended March 31, 2022. GCM Grosvenor’s Board of Directors also increased the firm’s stock and warrant repurchase authorization by $20 million, from $45 million to $65 million. “The first quarter of 2022 was a good one for GCM Grosvenor with regard to fundraising, revenue growth, and profitability,” said Michael Sacks, Chairman and Chief Executive Officer of GCM Grosvenor. “Our broad, diversified platform is built to perform for shareholders and investors in turbulent markets and to capitalize on opportunities arising from such environments.” Assets Under ManagementAssets Under Management (“AUM”) increased 10% from March 31,...

Prelude remains on track for clinical data readouts and next steps for the PRMT5 program, MCL1 inhibitor PRT1419, and CDK9 inhibitor PRT2527 in 2H2022 Strong cash and cash equivalents of $266.2 million as of March 31, 2022, expected to fund operations into 2H2024 WILMINGTON, Del., May 10, 2022 (GLOBE NEWSWIRE) — Prelude Therapeutics Incorporated (“Prelude”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2022, and provided an update on recent clinical and development pipeline progress. “Prelude continues to make great progress in discovering and advancing a diverse pipeline of differentiated small molecules, and with our current cash runway, we have the opportunity to deliver on numerous meaningful milestones. I’m delighted to have Jane onboard...

TORONTO, May 10, 2022 (GLOBE NEWSWIRE) — Stack Capital Group Inc., (“Stack Capital” or the “Company”) (TSX: STCK and STCK.WT) today announced its financial results for the first quarter ended March 31, 2022. Stack Capital reports all amounts in Canadian Dollars unless otherwise stated. Company Commentary:As at March 31, 2022, Book Value per Share of the Company was $11.95 and its cash position was $67 million To date, the Company has completed 6 investments into the following companies:SpaceX(space exploration & communications)Prove Identity, Inc.(cyber-security)Hopper, Inc.(travel & leisure)Newfront Insurance, Inc.(insurance & benefits)Bolt Financial, Inc.(e-commerce)Varo(neo-banking)Recent dislocations in the public markets have created investment opportunities across...

First quarter 2022 revenue up 188% year-over-year and gross profit of $10.1 million Company raises railcar delivery outlook and provides revenue guidance for fiscal year 2022 CHICAGO, May 10, 2022 (GLOBE NEWSWIRE) — FreightCar America, Inc. (“FCA” or the “Company”) (NASDAQ: RAIL), a diversified manufacturer of railroad freight cars, today reported results for the first quarter ended March 31, 2022. Business Highlights        First quarter 2022 revenue of $93.2 million, up 188% year-over-year, on deliveries of 783 railcars Gross profit of $10.1 million with gross margin of 10.8%, positive for the sixth consecutive quarter Manufacturing operating income of $8.5 million, positive for the fourth consecutive quarter First quarter 2022 net loss of ($25.8) million, or ($1.11) per share, primarily driven by a $20.7 million non-cash...